The Combination Tenofovir/Lamivudine (Emtricitabine) /Efavirenz (Nevirapine) Better Tolerated Than Zidovudine/Lamivudine/Nevirapine in a Prospective Observational Study of Adverse Effects in Newly Treated Individuals in Burkina Faso

Trial Profile

The Combination Tenofovir/Lamivudine (Emtricitabine) /Efavirenz (Nevirapine) Better Tolerated Than Zidovudine/Lamivudine/Nevirapine in a Prospective Observational Study of Adverse Effects in Newly Treated Individuals in Burkina Faso

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs Efavirenz (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Nevirapine (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Abacavir; Lopinavir; Zidovudine
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Oct 2015 New trial record
    • 26 Aug 2015 Results presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top